Beverly S. Mitchell, M.D.

Clinical Focus

• Cancer > Hematology
• Cancer > Hematology > Hematologic Malignancies
• Cancer > Lymphoma
• Hematology

Administrative Appointments

• Director, Stanford Cancer Center , (2008– present )
• Deputy Director, Stanford Cancer Center , (2005– 2008 )

Honors and Awards

• President, American Society of Hematology (2001)
• Member, American Society for Clinical Investigation (to present)
• Member, Association of American Professors (1991)
• Stohlman Award, Leukemia Society of America (1988)
• National Academy of Sciences, Institute of Medicine (Inducted 2001)

Professional Education

• Board Certification: Hematology, American Board of Internal Medicine (1978)
• University Hospital Zurich (1973) Switzerland
• University of Michigan Hospital (1977) MI
• Board Certification: Internal Medicine, American Board of Internal Medicine (1973)
• University of Washington (1973) WA
• Harborview Medical Center (1970) WA
• Harvard Medical School (1969) MA
• M.D., Harvard Medical School Medicine (1969)

Research Interests

Beverly S. Mitchell, MD, is the Director of the Stanford Cancer Center, and is the George E. Becker Professor of Medicine at Stanford University. Before joining the Stanford faculty, Dr. Mitchell lead the Molecular Therapeutics Program at UNC Chapel Hill's Lineberger Comprehensive Cancer Center, where she also served as Associate Director for Translational Research and Chief of the Division of Hematology/Oncology.

Dr. Mitchell received a bachelors degree in biochemistry from Smith College in Massachusetts and received her MD from Harvard Medical School. She completed her medical training as Chief Resident at the University of Washington. After completing a research fellowship at the Metabolic Laboratory at the University of Zurich in Switzerland she was awarded a Hematology Fellowship at the University of Michigan. Dr. Mitchell was a faculty member in the Departments of Medicine and Pharmacology at the University of Michigan for 16 years before moving to UNC.

Bev Mitchell has authored over 130 peer-reviewed articles. She served as President of the American Society of Hematology (ASH) and was Chair of the Medical and Scientific Affairs Committee and Vice Chair for Medical and Scientific Affairs of the Leukemia and Lymphoma Society of America.

Dr. Mitchell's research relates to the development of new therapies for hematologic malignancies. She has a long-standing interest in IMPDH as a therapeutic target and has published extensively on the regulation of this enzyme and the potential role of inhibitors in the treatment of leukemia in preclinical and clinical investigations.

Clinical Trials

• Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Completed

Publications

• Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic Acid by GTP. Ji Y,  Gu J, Makhov AM, Griffith JD, Mitchell BS.  J Biol Chem.  2006; 281 (1): 206-12
• The 5'-nucleotidases as regulators of nucleotide and drug metabolism. Hunsucker SA,  Mitchell BS, Spychala J.  Pharmacol Ther.  2005; 107 (1): 1-30
• Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. Kurtzberg J,  Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS.  J Clin Oncol.  2005; 23 (15): 3396-403
• Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Gu JJ,  Santiago L, Mitchell BS.  Blood.  2005; 105 (8): 3270-7
• Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer. Spychala J,  Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, Mitchell BS.  Clin Cancer Res.  2004; 10 (2): 708-17
• Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. Mahajan KN,  Mitchell BS.  Proc Natl Acad Sci U S A.  2003; 100 (19): 10746-51
• Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Huang M,  Itahana K, Zhang Y, Mitchell BS.  Cancer Res.  2009; 69 (7): 3004-12
• Tenascin C interacts with ecto-5'-nucleotidase (eN) and regulates adenosine generation in cancer cells Sadej R,  Inai K, Rajfur Z, Ostapkowicz A, Kohler J, Skladanowski AC, Mitchell BS, Spychala J.  Biochem Biophys Acta.  2008; 1782 (1): 35-40
• Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar proteins Huang M,  Ji Y, Itahana K, Zhang Y, Mitchell BS.  Leuk Res.  2008; 32 (1): 131-141
• Guanine nucleotide depletion mediates translocation of nucleolar proteins, including RNA helicase A (DHX-9). Huang M,  Mitchell BS.  Nucleosides Nucleotides Nucleic Acids.  2008; 27 (6): 704-11
• Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H. Huang M,  Wang Y, Gu J, Yang J, Noel K, Mitchell BS, Schramm VL, Graves LM.  Leuk Res.  2008; 32 (8): 1268-78
• Nelarabing induces complete remissions in adults with relapsed or refractory t-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801 DeAngelo D,  Yu D, Johnson J, Coutre S, Stone R, Stopeck A, Gockerman J, Mitchell B, Appelbaum F, Larson R.  Blood.  2007; 109 (12): 5136-5142
• Effect of lysosphatidic acid acyltransferase-B inhibition in acute luekemia Douvas MG,  Hogan KN, Ji Y, Holleneck D, Bonham L, Singer JW, Mitchell BS.  Leu Res.  2006; 30 (8): 1027-1036
• ACCO: ASCO core curriculum outline. Muss HB,  Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PW, Saltz L, Schapira L, Sparano J.  J Clin Oncol.  2005; 23 (9): 2049-77
• Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Orlowski RZ,  Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC.  Blood.  2005; 105 (8): 3058-65
• On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa. Aherne A,  Kennan A, Kenna PF, McNally N, Lloyd DG, Alberts IL, Kiang AS, Humphries MM, Ayuso C, Engel PC, Gu JJ, Mitchell BS, Farrar GJ, Humphries P.  Hum Mol Genet.  2004; 13 (6): 641-50
• Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. Malek K,  Boosalis MS, Waraska K, Mitchell BS, Wright DG.  Leuk Res.  2004; 28 (11): 1125-36
• Regulation of equilibrative nucleoside uptake by protein kinase inhibitors. Huang M,  Wang Y, Mitchell BS, Graves LM.  Nucleosides Nucleotides Nucleic Acids.  2004; 23 (8-9): 1445-50
• Inhibition of nucleoside transport by protein kinase inhibitors. Huang M,  Wang Y, Cogut SB, Mitchell BS, Graves LM.  J Pharmacol Exp Ther.  2003; 304 (2): 753-60
• Induction of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide depletion. Gu JJ,  Gathy K, Santiago L, Chen E, Huang M, Graves LM, Mitchell BS.  Blood.  2003; 101 (12): 4958-65
• The proteasome--an emerging therapeutic target in cancer. Mitchell BS,  N Engl J Med.  2003; 348 (26): 2597-8
• Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice. Gu JJ,  Tolin AK, Jain J, Huang H, Santiago L, Mitchell BS.  Mol Cell Biol.  2003; 23 (18): 6702-12
• A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools. Huang M,  Wang Y, Collins M, Mitchell BS, Graves LM.  Mol Pharmacol.  2002; 62 (3): 463-72
• Association of DNA polymerase mu (pol mu) with Ku and ligase IV: role for pol mu in end-joining double-strand break repair. Mahajan KN,  Nick McElhinny SA, Mitchell BS, Ramsden DA.  Mol Cell Biol.  2002; 22 (14): 5194-202
• Inhibition of nucleoside transport by p38 MAPK inhibitors. Huang M,  Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM.  J Biol Chem.  2002; 277 (32): 28364-7
• Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Rodriguez CO,  Mitchell BS, Ayres M, Eriksson S, Gandhi V.  Cancer Res.  2002; 62 (11): 3100-5
• Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes. Spychala J,  Mitchell BS.  J Lab Clin Med.  2002; 140 (2): 84-91
• Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. van Deventer HW,  Hall MD, Orlowski RZ, Mitchell BS, Berkowitz LR, Hogan C, Dunphy CH, Koehler J, Shea TC.  Am J Hematol.  2002; 71 (3): 184-90
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Orlowski RZ,  Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL.  J Clin Oncol.  2002; 20 (22): 4420-7
• Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Rai KR,  Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L.  J Clin Oncol.  2002; 20 (18): 3891-7
• Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Blackstock AW,  Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS, Swarts SG, Hess SM.  Clin Cancer Res.  2001; 7 (10): 3263-8
• Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance. Hunsucker SA,  Spychala J, Mitchell BS.  J Biol Chem.  2001; 276 (13): 10498-504
• Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. Gu JJ,  Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L, Mitchell BS.  J Clin Invest.  2000; 106 (4): 599-606
• The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Mitchell BS,  Schumacher U.  Histol Histopathol.  1999; 14 (1): 217-26
• Association of terminal deoxynucleotidyl transferase with Ku. Mahajan KN,  Gangi-Peterson L, Sorscher DH, Wang J, Gathy KN, Mahajan NP, Reeves WH, Mitchell BS.  Proc Natl Acad Sci U S A.  1999; 96 (24): 13926-31
• Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region. Spychala J,  Zimmermann AG, Mitchell BS.  J Biol Chem.  1999; 274 (32): 22705-12
• Nucleotide pool imbalance and adenosine deaminase deficiency induce alterations of N-region insertions during V(D)J recombination. Gangi-Peterson L,  Sorscher DH, Reynolds JW, Kepler TB, Mitchell BS.  J Clin Invest.  1999; 103 (6): 833-41
• ATP and phosphate reciprocally affect subunit association of human recombinant High Km 5'-nucleotidase. Role for the C-terminal polyglutamic acid tract in subunit association and catalytic activity. Spychala J,  Chen V, Oka J, Mitchell BS.  Eur J Biochem.  1999; 259 (3): 851-8
• Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes Laliberte J,  Yee A, Xiong Y, Mitchell BS.  Blood.  1998; 2896-2904
• Lectin histochemistry of human leukaemic mast cells (HMC-1) transplanted into severe combined immunodeficient (scid) mice. Schumacher U,  van Damme EJ, Peumans WJ, Butterfield JH, Mitchell BS.  Acta Histochem.  1998; 100 (1): 1-9
• Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Zimmermann AG,  Gu JJ, Laliberté J, Mitchell BS.  Prog Nucleic Acid Res Mol Biol.  1998; 61 181-209
• Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. Gandhi V,  Plunkett W, Rodriguez CO, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ.  J Clin Oncol.  1998; 16 (11): 3607-15
• Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Laliberté J,  Yee A, Xiong Y, Mitchell BS.  Blood.  1998; 91 (8): 2896-904
• Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5' palindromic octamer sequence. Zimmermann AG,  Wright KL, Ting JP, Mitchell BS.  J Biol Chem.  1997; 272 (36): 22913-23
• Cellular delivery of nucleoside diphosphates: a prodrug approach. Kang SH,  Sinhababu AK, Cory JG, Mitchell BS, Thakker DR, Cho MJ.  Pharm Res.  1997; 14 (6): 706-12
• Adenosine metabolism during phorbol myristate acetate-mediated induction of HL-60 cell differentiation: changes in expression pattern of adenosine kinase, adenosine deaminase, and 5'-nucleotidase. Spychala J,  Mitchell BS, Barankiewicz J.  J Immunol.  1997; 158 (10): 4947-52
• Regulation of the human inosine monophosphate dehydrogenase type I gene. Utilization of alternative promoters. Gu JJ,  Spychala J, Mitchell BS.  J Biol Chem.  1997; 272 (7): 4458-66
• Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Hapke DM,  Stegmann AP, Mitchell BS.  Cancer Res.  1996; 56 (10): 2343-7
• A 73 year-old woman with anemia and thrombocytopenia Mitchell B,  Brecher M.  J Am Ger Soc.  1996; (44): 723-726
• Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Spychala J,  Datta NS, Takabayashi K, Datta M, Fox IH, Gribbin T, Mitchell BS.  Proc Natl Acad Sci U S A.  1996; 93 (3): 1232-7
• Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes. Zimmermann A,  Gu JJ, Spychala J, Mitchell BS.  Adv Enzyme Regul.  1996; 36 75-84
• Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Manome Y,  Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA.  Nat Med.  1996; 2 (5): 567-73
• Transcriptional regulationof the IMPDH type I and II genes Zimmermann A,  Gu JJ, Spychala j, Mitchell BS.  Adv Enzyme Regul.  1996; (36): 75-84
• Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. Chen EH,  Johnson EE, Vetter SM, Mitchell BS.  J Clin Invest.  1995; 95 (4): 1660-8
• Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Hager PW,  Collart FR, Huberman E, Mitchell BS.  Biochem Pharmacol.  1995; 49 (9): 1323-9
• Characterization of the human inosine-5'-monophosphate dehydrogenase type II gene. Zimmermann AG,  Spychala J, Mitchell BS.  J Biol Chem.  1995; 270 (12): 6808-14
• GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Catapano CV,  Dayton JS, Mitchell BS, Fernandes DJ.  Mol Pharmacol.  1995; 47 (5): 948-55
• Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Flasshove M,  Strumberg D, Ayscue L, Mitchell BS, Tirier C, Heit W, Seeber S, Schütte J.  Leukemia.  1994; 8 (5): 780-5
• Assignment of the human type I IMP dehydrogenase gene (IMPDH1) to chromosome 7q31.3-q32). Gu JJ,  Kaiser-Rogers K, Rao K, Mitchell BS.  Genomics.  1994; 24 (1): 179-81
• Regulation of low Km (ecto-) 5'-nucleotidase gene expression in leukemic cells. Spychala J,  Mitchell BS.  Adv Exp Med Biol.  1994; 370 683-7
• Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. Dayton JS,  Lindsten T, Thompson CB, Mitchell BS.  J Immunol.  1994; 152 (3): 984-91
• Hereditary overexpression of adenosine deaminase in erythrocytes: studies in erythroid cell lines and transgenic mice. Chen EH,  Mitchell BS.  Blood.  1994; 84 (7): 2346-53
• Type I inosine monophosphate dehydrogenase: evidence for a single functional gene in mammalian species. Dayton JS,  Mitchell BS.  Biochem Biophys Res Commun.  1993; 195 (2): 897-901
• Regulation of human deoxycytidine kinase expression. Mitchell BS,  Song JJ, Johnson EE, Chen E, Dayton JS.  Adv Enzyme Regul.  1993; 33 61-8
• Genomic structure and chromosomal localization of the human deoxycytidine kinase gene. Song JJ,  Walker S, Chen E, Johnson EE, Spychala J, Gribbin T, Mitchell BS.  Proc Natl Acad Sci U S A.  1993; 90 (2): 431-4
• Hereditary overexpression of adenosine deaminase in erythrocytes: evidence for a cis-acting mutation. Chen EH,  Tartaglia AP, Mitchell BS.  Am J Hum Genet.  1993; 53 (4): 889-93
• IMP dehydrogenase inhibitors as immunomodulators. Mitchell BS,  Dayton JS, Turka LA, Thompson CB.  Ann N Y Acad Sci.  1993; 685 217-24
• Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Owens JK,  Shewach DS, Ullman B, Mitchell BS.  Cancer Res.  1992; 52 (9): 2389-93
• Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Dayton JS,  Turka LA, Thompson CB, Mitchell BS.  Mol Pharmacol.  1992; 41 (4): 671-6
• Development of an in vitro model system to study the physiologic effects and toxicities of immunosuppressants Thompson CB,  Jackson KM, Turka LA, Mitchell BS, June CH.  Alternative Methods in Toxicology.  1991; 8 55-61
• Guanine ribonucleotide depletion inhibits T cell activation. Dayton JS,  Turka LA, Thompson CB, Mitchell BS.  Adv Exp Med Biol.  1991; 309B 293-6
• Cloning and expression of human deoxycytidine kinase cDNA. Chottiner EG,  Shewach DS, Datta NS, Ashcraft E, Gribbin D, Ginsburg D, Fox IH, Mitchell BS.  Proc Natl Acad Sci U S A.  1991; 88 (4): 1531-5
• Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. Turka LA,  Dayton J, Sinclair G, Thompson CB, Mitchell BS.  J Clin Invest.  1991; 87 (3): 940-8
• CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Hanson CA,  Gribbin TE, Schnitzer B, Schlegelmilch JA, Mitchell BS, Stoolman LM.  Blood.  1990; 76 (11): 2360-7
• Mutations induced at the hypoxanthine-guanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate pools. Mattano SS,  Palella TD, Mitchell BS.  Cancer Res.  1990; 50 (15): 4566-71
• Identification of an Apa I polymorphism within the human adenosine deaminase gene Gribbin TE,  Chottiner E, Ginsburg D, Mitchell BS.  Nucl Acids Res.  1989; (17): 3626
• Erythrocyte adenosine deaminase overproduction in hereditary hemolytic anemia. Chottiner EG,  Ginsburg D, Tartaglia AP, Mitchell BS.  Blood.  1989; 74 (1): 448-53
• Association of a mature B cell leukemia with a 4p+ chromosomal abnormality: derivation and characterization of a cell line. Gribbin TE,  Stein CK, Harrison JS, Glover TW, Hanson CA, Wasmuth JJ, Cody RL, Mitchell BS.  Leukemia.  1989; 3 (9): 643-7
• Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. Datta NS,  Shewach DS, Mitchell BS, Fox IH.  J Biol Chem.  1989; 264 (16): 9359-64
• Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells. Shewach DS,  Mitchell BS.  Cancer Res.  1989; 49 (23): 6498-502
• Autosomal dominant hemolytic anemia and adenosine deaminase overproduction. Chottiner EG,  Ginsburg D, Mitchell BS.  Adv Exp Med Biol.  1989; 253A 493-7
• Erythrocyte-specific overproduction of adenosine deaminase: molecular genetic studies. Chottiner EG,  Gribbin TE, Ginsburg D, Mitchell BS.  Prog Clin Biol Res.  1989; 319 55-64; discussion 65-8
• Properties of highly purified human T lymphoblast (MOLT-4) deoxycytidine kinase. Datta NS,  Shewach DS, Hurley MC, Mitchell BS, Fox IH.  Adv Exp Med Biol.  1989; 253B 87-92
• Human T-lymphoblast deoxycytidine kinase: purification and properties. Datta NS,  Shewach DS, Hurley MC, Mitchell BS, Fox IH.  Biochemistry.  1989; 28 (1): 114-23
• Elevated adenosine deaminase activity and hereditary hemolytic anemia. Evidence for abnormal translational control of protein synthesis. Chottiner EG,  Cloft HJ, Tartaglia AP, Mitchell BS.  J Clin Invest.  1987; 79 (3): 1001-5
• Transcriptional regulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 in HL-60 promyelocytic leukemia cells. Simpson RU,  Hsu T, Begley DA, Mitchell BS, Alizadeh BN.  J Biol Chem.  1987; 262 (9): 4104-8
• Genetic expression of adenosine deaminase in human lymphoid malignancies. Gan TE,  Dadonna PE, Mitchell BS.  Blood.  1987; 69 (5): 1376-80
• Molecular basis for elevated adenosine deaminase activity in a kindred with hemolytic anemia Chottiner EG,  Cloft H, Tartaglia A, Mitchell BS.  J Clin Invest.  1987; 1001-1005
• Characterization of arabinosylguanine resistance in a lymphoblastoid cell line. Shewach DS,  Mitchell BS.  Adv Exp Med Biol.  1986; 195 Pt B 605-9
• Differential metabolism of deoxyribonucleosides by leukaemic T cells of immature and mature phenotype Sidi Y,  Edwards N, Winkler C, Bunn P, Mitchell B.  Br J Haemat.  1985; (61): 125-134
• Differential metabolism of deoxyribonucleosides by leukaemic T cells of immature and mature phenotype. Sidi Y,  Edwards NL, Winkler C, Bunn P, Mitchell BS.  Br J Haematol.  1985; 61 (1): 125-34
• Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Shewach DS,  Daddona PE, Ashcraft E, Mitchell BS.  Cancer Res.  1985; 45 (3): 1008-14
• Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia. Mitchell BS,  Sidi Y, Hershfield M, Koller CA.  Ann N Y Acad Sci.  1985; 451 129-37
• Effects of guanine ribonucleotide accumulation on the metabolism and cell cycle of human lymphoid cells. Sidi Y,  Hudson JL, Mitchell BS.  Cancer Res.  1985; 45 (10): 4940-5
• Differential metabolism of guanine nucleosides by human lymphoid cell lines. Mitchell BS,  Sidi Y.  Proc Soc Exp Biol Med.  1985; 179 (4): 427-31
• Z-nucleotide accumulation in erythrocytes from Lesch-Nyhan patients. Sidi Y,  Mitchell BS.  J Clin Invest.  1985; 76 (6): 2416-9
• 2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. Sidi Y,  Mitchell BS.  J Clin Invest.  1984; 74 (5): 1640-8
• Erythrocyte ATP a dATP measurements predict toxicity following 2'-deoxycoformycin therapy Koller C,  Mitchell B.  Cancer Treat Symp.  1984; (2): 67-74
• Plasma membrane 5'-nucleotidase and other purine enzymes in murine lymphocytes. Edwards NL,  Mitchell BS, Fox IH, Mond JJ.  Adv Exp Med Biol.  1984; 165 Pt B 129-32
• Purine metabolizing enzymes as predictors of lymphoblast sensitivity to deoxyadenosine. Mitchell BS,  Edwards NL.  J Lab Clin Med.  1984; 104 (3): 414-24
• Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation. Daddona PE,  Mitchell BS, Meuwissen HJ, Davidson BL, Wilson JM, Koller CA.  J Clin Invest.  1983; 72 (2): 483-92
• Deoxyribonucleoside triphosphate accumulation by leukemic cells. Mitchell BS,  Edwards NL, Koller CA.  Blood.  1983; 62 (2): 419-24
• S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine. Hershfield MS,  Kredich NM, Koller CA, Mitchell BS, Kurtzberg J, Kinney TR, Falletta JM.  Cancer Res.  1983; 43 (7): 3451-8
• Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy. Koller CA,  Mitchell BS.  Cancer Res.  1983; 43 (3): 1409-14
• Deficiencies of adenosine deaminase and purine nucleoside phosphorylase: Implimcations for immunopharmacology Mitchell BS,  Med Gr Rounds.  1982; (1): 85-93
• Adult T-cell leukaemia-lymphoma with unusual phenotype Schnitzer B,  Lovett E, Hudson J, McClatchey K, Keren D, Dabich L, Mitchell B.  The Lancet (Letter).  1982; 1273-1274
• Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts. Kazmers IS,  Mitchell BS, Dadonna PE, Wotring LL, Townsend LB, Kelley WN.  Science.  1981; 214 (4525): 1137-9
• Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo. Mitchell BS,  Koller CA, Heyn R.  Blood.  1980; 56 (3): 556-9
• ATP depletion as a consequence of adenosine deaminase inhibition in man. Siaw MF,  Mitchell BS, Koller CA, Coleman MS, Hutton JJ.  Proc Natl Acad Sci U S A.  1980; 77 (10): 6157-61
• An assay of deoxyadenosine and adenosine in human plasma by HPLC. Koller CA,  Stetson PL, Nichamin LD, Mitchell BS.  Biochem Med.  1980; 24 (2): 179-84
• Multiple myeloma: current concepts in diagnosis and management. Paredes JM,  Mitchell BS.  Med Clin North Am.  1980; 64 (4): 729-42
• Purinogenic immunodeficiency diseases: clinical features and molecular mechanisms. Mitchell BS,  Kelley WN.  Ann Intern Med.  1980; 92 (6): 826-31
• Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition. Koller CA,  Mitchell BS, Grever MR, Mejias E, Malspeis L, Metz EN.  Cancer Treat Rep.  1979 Nov-Dec; 63 (11-12): 1949-52
• Possible role for 5'-nucleotidase in deoxyadenosine selective toxicity to cultured human lymphoblasts. Wortmann RL,  Mitchell BS, Edwards NL, Fox IH.  Adv Exp Med Biol.  1979; 122B 243-59
• Molecular mechanism(s) of deoxyribonucleoside toxicity in T-lymphoblasts. Wilson JM,  Mitchell BS, Kelley WN.  Adv Exp Med Biol.  1979; 122B 265-70
• Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin. Mitchell BS,  Koller CA, Kelley WN.  Adv Exp Med Biol.  1979; 122B 347-50
• Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. Wortmann RL,  Mitchell BS, Edwards NL, Fox IH.  Proc Natl Acad Sci U S A.  1979; 76 (5): 2434-7
• Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts. Wilson JM,  Mitchell BS, Daddona PE, Kelley WN.  J Clin Invest.  1979; 64 (5): 1475-84
• Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Mitchell BS,  Mejias E, Daddona PE, Kelley WN.  Proc Natl Acad Sci U S A.  1978; 75 (10): 5011-4
• Uridine diphosphate galactose 4'-epimerase deficiency Gitzelmann R,  Steinmann B, Mitchell B, Haigis E..  Helv Paediat Acta.  1976; IV (31): 441-454
• Reversal of UDP-galactose 4-epimerase deficiency of human leukocytes in culture Mitchell B,  Haigis E, Steinmann B, Gitzelmann R.  Proc Nat Acad Sci (USA).  1975; (72): 5026-5030
• Granulocyte and erythroid colony forming cells from rat marrow: Studies of physical and cell cycle characteristics and competition for expression Mitchell B,  Adamson J.  In Erythropoiesis, Nakao K, Fisher J, Pakaku F (Eds) University Park Press.  1975;
• Epidemiological aspects of neoplastic disorders in Israeli migrant population. V. The lymphomas. Modan B,  Goldman B, Shani M, Meytes D, Mitchell BS.  J Natl Cancer Inst.  1969; 42 (3): 375-81
• The effect of phenylthiourea on melanogenesis of Fundulus Heteroclitus Bamford S,  Cassin C, Mitchell B..  Biological Bulletin.  1966; (131): 398-399
• Sex chromatin determinations in selected cases of developmental sex abnormalities with an assessment of results. BAMFORD SB,  CASSIN CM, MITCHELL BS.  Acta Cytol.  1963 May-Jun; 7 151-8